Levetiracetam Zentiva (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release and stabilizes neuronal firing. This reduces abnormal neuronal excitability and helps prevent the spread of seizure activity in the central nervous system.

The dosage of Levetiracetam Zentiva is determined by the prescribing clinician based on the patient’s age, weight, renal function, and clinical response. The prescriber will set the appropriate dose and administration schedule.

Levetiracetam’s pregnancy category is unknown, and safety data are limited. It should only be used during pregnancy or lactation if the potential benefit justifies the possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Levetiracetam has a distinct mechanism targeting SV2A and generally exhibits fewer drug‑drug interactions than many enzyme‑inducing antiepileptics such as carbamazepine. It is often preferred for patients who require a medication with a low interaction profile and rapid intravenous administration.

Levetiracetam Zentiva should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Follow the manufacturer’s instructions for handling to maintain product stability.

Levetiracetam Zentiva is administered intravenously as an injectable solution. The infusion rate and volume are determined by the healthcare professional, who will follow institutional protocols for IV administration.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, depression or suicidal ideation, anaphylactic reactions, and rare blood disorders. Patients should be monitored closely for any signs of these conditions, and treatment should be discontinued if they occur.

Levetiracetam Zentiva is contraindicated in patients with known hypersensitivity to levetiracetam or any of the formulation components. Caution is also advised for individuals with severe renal impairment where dose adjustment may not be feasible.